Christina H Ruhlmann1, Franziska Jahn2, Karin Jordan2, Kristopher Dennis3, Ernesto Maranzano4, Alexander Molassiotis5, Fausto Roila6, Petra Feyer7. 1. Department of Oncology, Odense University Hospital, Sdr. Boulevard 29, DK-5000, Odense C, Denmark. c.ruhlmann@dadlnet.dk. 2. Department of Hematology and Oncology, Martin-Luther University Halle-Wittenberg, Halle, Germany University of Halle, Ernst Grube Strasse 40, Halle, Germany. 3. Division of Radiation Oncology, Ottawa Hospital Research Institute, University of Ottawa, 501 Smyth Road, Ottawa, Ontario, K1H8L6, Canada. 4. Departement of Oncology, Radiation Oncology Centre, Azienda Ospedaliera S. Maria, Via T. di Joannuccio 1, 05100, Terni, Italy. 5. School of Nursing, The Hong Kong Polytechnic University, 11 Yuk Choi Rd, Hung Hom, Hong Kong, China. 6. Departement of Oncology, Medical Oncology Division, Azienda Ospedaliera S. Maria, Via T. di Joannuccio 1, 05100, Terni, Italy. 7. Department of Radiation Oncology, Vivantes Clinics Neukoelln, Rudower Str. 48, 12351, Berlin, Germany.
Abstract
PURPOSE: Radiotherapy-induced nausea and vomiting (RINV) are distressing symptoms. Evidence-based guidelines should facilitate the prescription of the best possible antiemetic prophylaxis. As part of the MASCC/ESMO Antiemetic Guidelines Update 2016, a thorough review of the literature concerning RINV since the 2009 update was required. METHODS: A systematic review of the literature including data published from June 2009 to May 2015 was performed. Committee VII (RINV) under the MASCC/ESMO Antiemetic Guidelines Update Committee assessed the literature. RESULTS: The searches yielded 926 records, 906 records were excluded, leaving 20 records for full text assessment, and 18 publications were finally included. The only fully published randomized studies in prevention of RINV were two negative studies in acupuncture and green tea, respectively. No data to support new recommendations for antiemetic prophylaxis in RINV was available. However, based on expert opinions, the committee agreed on changes in emetic risk level for certain sites of irradiation. CONCLUSIONS: The serotonin receptor antagonists are still the corner stone in antiemetic prophylaxis of nausea and vomiting induced by high and moderate emetic risk radiotherapy. The studies available since the last update did not change recommendations for antiemetic prophylaxis. The emetogenicity of craniospinal radiotherapy was reclassified from low to moderate emetic level along with some other minor changes. In the future, RINV prophylaxis in single fraction, multiple fraction, and in concomitant chemo-radiotherapy still need to be explored with regard to the different classes and combinations of antiemetic drugs.
PURPOSE: Radiotherapy-induced nausea and vomiting (RINV) are distressing symptoms. Evidence-based guidelines should facilitate the prescription of the best possible antiemetic prophylaxis. As part of the MASCC/ESMO Antiemetic Guidelines Update 2016, a thorough review of the literature concerning RINV since the 2009 update was required. METHODS: A systematic review of the literature including data published from June 2009 to May 2015 was performed. Committee VII (RINV) under the MASCC/ESMO Antiemetic Guidelines Update Committee assessed the literature. RESULTS: The searches yielded 926 records, 906 records were excluded, leaving 20 records for full text assessment, and 18 publications were finally included. The only fully published randomized studies in prevention of RINV were two negative studies in acupuncture and green tea, respectively. No data to support new recommendations for antiemetic prophylaxis in RINV was available. However, based on expert opinions, the committee agreed on changes in emetic risk level for certain sites of irradiation. CONCLUSIONS: The serotonin receptor antagonists are still the corner stone in antiemetic prophylaxis of nausea and vomiting induced by high and moderate emetic risk radiotherapy. The studies available since the last update did not change recommendations for antiemetic prophylaxis. The emetogenicity of craniospinal radiotherapy was reclassified from low to moderate emetic level along with some other minor changes. In the future, RINV prophylaxis in single fraction, multiple fraction, and in concomitant chemo-radiotherapy still need to be explored with regard to the different classes and combinations of antiemetic drugs.
Authors: Kristopher Dennis; Liying Zhang; Stephen Lutz; Angela van Baardwijk; Yvette van der Linden; Tanya Holt; Palmira Foro Arnalot; Jean-Léon Lagrange; Ernesto Maranzano; Rico Liu; Kam-Hung Wong; Lea-Choung Wong; Vassilios Vassiliou; Benjamin W Corn; Carlo De Angelis; Lori Holden; C Shun Wong; Edward Chow Journal: Int J Radiat Oncol Biol Phys Date: 2012-06-15 Impact factor: 7.038
Authors: Victor H F Lee; Sherry C Y Ng; T W Leung; Gordon K H Au; Dora L W Kwong Journal: Int J Radiat Oncol Biol Phys Date: 2012-01-13 Impact factor: 7.038
Authors: Michael Poon; Kristopher Dennis; Carlo DeAngelis; Hans Chung; Jordan Stinson; Liying Zhang; Gillian Bedard; Marko Popovic; Nicholas Lao; Natalie Pulenzas; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2014-01-12 Impact factor: 3.603
Authors: Alexander Molassiotis; Matti Aapro; Mario Dicato; Pere Gascon; Sylvia A Novoa; Nicolas Isambert; Thomas A Burke; Anna Gu; Fausto Roila Journal: J Pain Symptom Manage Date: 2013-09-24 Impact factor: 3.612
Authors: Kristopher Dennis; Janet Nguyen; Roseanna Presutti; Carlo DeAngelis; May Tsao; Cyril Danjoux; Elizabeth Barnes; Arjun Sahgal; Lori Holden; Florencia Jon; Shun Wong; Edward Chow Journal: Support Care Cancer Date: 2011-09-08 Impact factor: 3.603
Authors: Ernesto Maranzano; Verena De Angelis; Stefano Pergolizzi; Marco Lupattelli; Paolo Frata; Stefano Spagnesi; Maria Luisa Frisio; Giovanni Mandoliti; Giuseppe Malinverni; Fabio Trippa; Letizia Fabbietti; Salvatore Parisi; Annamaria Di Palma; Pietro De Vecchi; Costantino De Renzis; Celestino Giorgetti; Tiziano Bergami; Roberto Orecchia; Maurizio Portaluri; Marco Signor; Davide Di Gennaro Journal: Radiother Oncol Date: 2009-12-04 Impact factor: 6.280
Authors: Anna Enblom; Beata Bergius Axelsson; Gunnar Steineck; Mats Hammar; Sussanne Börjeson Journal: Support Care Cancer Date: 2008-06-05 Impact factor: 3.603
Authors: Franziska Jahn; Bernhard Wörmann; Juliane Brandt; Annette Freidank; Petra Feyer; Karin Jordan Journal: Dtsch Arztebl Int Date: 2022-05-27 Impact factor: 8.251
Authors: R de Las Peñas; A Blasco; J De Castro; Y Escobar; R García-Campelo; A Gúrpide; R Lopez-Lopez; M Majem; C A Rodríguez; J A Virizuela Journal: Clin Transl Oncol Date: 2016-11-28 Impact factor: 3.405
Authors: Anna Enblom; Gunnar Steineck; Mats Hammar; Sussanne Börjeson Journal: Evid Based Complement Alternat Med Date: 2017-02-08 Impact factor: 2.629
Authors: Kristopher Dennis; Liang Zeng; Carlo De Angelis; Hans Chung; Natalie Coburn; Edward Chow; C Shun Wong Journal: Clin Transl Radiat Oncol Date: 2018-04-05